

Analytical study on certain abused drugs

Thesis

Presented for partial fulfillment of master degree in pharmaceutical sciences

(Pharmaceutical analytical chemistry)

By

David Shehata Fouad Georgy Nakhla

Bachelor degree of pharmaceutical sciences | Misr International University (2012)

Under the supervision of

Dr. Lobna Abd El-Aziz Hussein

Professor and head | Pharmaceutical analytical chemistry, faculty of Pharmacy, Ain Shams University (ASU)

Dr. Nancy Magdy Hanna

Assistant professor | Pharmaceutical analytical chemistry, faculty of Pharmacy, Ain Shams University (ASU)

Dr. Inas Ali Ibrahim Abdallah

Assistant professor | Analytical chemistry, faculty of pharmacy, University of Sadat City

Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy

Ain Shams University

2017

Approval sheet

Title of the Master degree in Pharmaceutical Sciences

(Pharmaceutical Analytical Chemistry)

Analytical study on certain abused drugs

Name of the Candidate:

David Shehata Fouad Georgy Nakhla

Submitted to:

Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, 2017.

Committee in Charge:

1- Prof. Dr. Lobna Abdel-Aziz Hussein

Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University.

2- Prof. Dr. Marian Nebsen Morkos

Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University.

3- Ass. Prof. Dr. Medhat Abd-elrahman elghobashy

Assistant Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University.

Acknowledgements

All the thanks and gratitude are to God for supporting me and providing me with all the strength, power and perseverance to get this work done, and for blessing me with great people and opportunities throughout my life who helped shape and develop my character and future to the better.

I would like to thank all the people who contributed in some way to the work described in this thesis. First and foremost, my deepest gratitude and appreciation are to **Prof. Lobna Abdel-Aziz Hussein**, Professor and head of Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy, Ain Shams University, for her wise supervision, generous assistance, continuous and unlimited encouragement and support. I am very fortunate and honored to be one of her students.

I would like to thank **Ass. Prof. Nancy Magdy Hanna**, Lecturer of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University for her valuable guidance and assistance throughout the practical work and for being always available and supportive anytime I needed her opinion and guidance. I am really honored and grateful to be one of her students

I would like to thank **Ass. Prof. Inas Ali Ibrahim Abdallah**, Lecturer of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, University of Sadat City for being a great mentor, advisor and role model. I really appreciate her extreme patience, wisdom, and persistence for getting the work done. Dr. Inas has taught me how to be a conscientious researcher and scientist by example, and I am extremely grateful for all what she has done for our research to reach the furthest heights possible. I am very thankful and honored to be one of her students.

I would like to thank **Ass. Prof. Hazem Hassan**, Assistant Professor and Director of the Pharmacokinetics and Biopharmaceutics Lab (PBL) at the Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland in Baltimore for inviting me to his research group and providing his valuable guidance and lab resources towards the completion of our designated research and animal studies.

I would like to thank all my colleagues in the Pharmaceutical Analytical Chemistry department at Misr International University, School of Pharmacy and my lab mates at the University of Maryland in Baltimore for all their valuable help and assistance.

Finally, I am very thankful to my parents, brother, and all my friends for always being there for me and for providing me with much needed support and encouragement that always helped me to overcome disappointments and setbacks and fueled me with energy to continue and finish well.

Contents

Part I: Introduction

I.1. Pain and analgesia	1
I.1.1. Pain killers classification	1
I.1.2. Mode of action of opioid analgesics	2
I.2. Prevalence of drug abuse	3
I.2.1. Methadone-cocaine co-abuse	3
I.2.2. Oxycodone abuse	5
I.2.3. Tramadol abuse	6
I.4. Our goal	6

Part II: Literature review

II.1. Methadone	7
II.1.1. Historical Background	7
II.1.2. Structure.....	7
II.1.3. Physical and Spectral Properties.....	8
II.1.4. Methods of analysis	8
II.1.4.1. Spectrophotometric methods	8
II.1.4.2. Electrochemical methods.....	8
II.1.4.3. Separation techniques	8
II.1.4.3.a. Electrophoretic methods	8
II.1.4.3.b. High-performance liquid chromatography methods	9
II.1.4.3.c. Gas Chromatographic methods	14
II.2. Oxycodone	15
II.2.1. Historical Background	15
II.2.2. Structure.....	15

II.2.3. Physical and Spectral Properties.....	16
II.2.4. Methods of analysis	16
II.2.4.1. Spectrophotometric methods	16
II.2.4.2. Separation techniques	16
II.2.4.2.a. High-performance liquid chromatography methods	16
II.2.4.2.b. Gas Chromatographic methods	22
II.2.4.2.c. Thin layer chromatography	23
II.3. Cocaine.....	24
II.3.1. Historical Background	24
II.3.2. Structure.....	24
II.3.3. Physical and Spectral Properties.....	25
II.3.4. Methods of analysis	25
II.3.4.1. Spectrophotometric methods	25
II.3.4.2. Electrochemical methods.....	25
II.3.4.3. Separation techniques	26
II.3.4.3.a. Electrophoretic methods	26
II.3.4.3.b. High-performance liquid chromatography methods	27
II.3.4.3.c. Gas Chromatographic methods	32
II.3.4.3.d. Thin layer chromatography	34
II.4. Tramadol	35
II.4.1. Historical Background	35
II.4.2. Structure.....	35
II.4.3. Physical and Spectral Properties.....	36
II.4.4. Methods of analysis	36
II.4.4.1. Spectrophotometric methods	36

II.4.4.2. Electrochemical methods.....	37
II.4.4.3. Separation techniques.....	38
II.4.4.3.a. Electrophoretic methods	38
II.4.4.3.b. High-performance liquid chromatography methods	39
II.4.4.3.c. Gas Chromatographic methods	55
II.4.4.3.d. Thin layer chromatography	58
II.5. Paracetamol	59
II.5.1. Historical Background	59
II.5.2. Structure.....	59
II.5.3. Physical and Spectral Properties.....	60
II.5.4. Methods of analysis.....	60
II.5.4.1. Spectrophotometric methods	60
II.5.4.2. Electrochemical methods.....	61
II.5.4.3. Separation techniques.....	62
II.5.4.3.a. Electrophoretic methods	62
II.5.4.3.b. High-performance liquid chromatography methods	63
II.5.4.3.c. Gas Chromatographic methods	69
II.5.4.3.d. Thin layer chromatography	70

Part III: Simultaneous determination of methadone and cocaine in rat serum and brain tissue samples by High-Performance Liquid Chromatography with dual UV detection

III.1. Introduction.....	71
III.2. Experimental	72
III.2.1. Apparatus	72
III.2.2. Samples	73

III.2.2.1. Pure standard.....	73
III.2.2.2. Rat serum sample.....	73
III.2.2.3. Rat brain tissue sample	73
III.2.3. Chemicals and reagents.....	73
III.2.4. Standard solutions and calibration curves.....	74
III.2.4.1. Standard stock solutions (1 mg/mL)	74
III.2.4.2. Standard working solutions.....	74
III.2.4.3. Calibration and quality control samples	74
III.2.5. Procedure	75
III.2.6. Method validation	75
III.2.6.1. Selectivity	75
III.2.6.2. Linearity and range	75
III.2.6.3. Accuracy and precision.....	76
III.2.6.4. Recovery	76
III.2.6.5. Stability	76
III.2.6.5.1. Freeze and thaw stability	77
III.2.6.5.2. Benchtop stability	77
III.2.6.5.3. Long-term stability.....	77
III.2.6.5.4. Processed sample stability	77
III.2.6.5.5. Stock solution stability.....	77
III.2.7. Applications	78
III.2.7.1. Application to rat serum and brain tissue samples	78
III.2.7.1.1. Extraction procedure for rat serum samples	78
III.2.7.1.2. Extraction procedure for rat brain tissue samples	79
III.2.7.1.3. Pharmacokinetic parameters	79

III.3. Results and discussion	79
III.3.1. Method development and optimization of chromatographic conditions	80
III.3.2. Optimization of sample extraction procedure.....	81
III.3.3. Selection of the internal standard.....	81
III.3.4. Method validation	82
III.3.4.1. Selectivity	82
III.3.4.2. Linearity and range	82
III.3.4.3. Accuracy and precision.....	83
III.3.4.4. Recovery	83
III.3.4.5. Stability	83
III.3.5. Application to rat serum and brain tissue samples for the quantification of methadone and cocaine	84
III.3.5.1. Pharmacokinetics parameters	84
III.4. Conclusion	85

Part IV: Determination of Oxycodone in rat serum and brain tissue samples by Ultra-Performance liquid chromatography-Tandem Mass-spectrometry (UPLC-MS/MS)

IV.1. Introduction.....	106
IV.2. Experimental	107
IV.2.1. Apparatus.....	107
IV.2.2. Samples.....	107
IV.2.2.1. Pure standard	107
IV.2.2.2. Rat serum sample.....	107
IV.2.2.3. Rat brain tissue sample	108
IV.2.3. Chemicals and reagents	108
IV.2.4. Standard solutions and calibration curves	108

IV.2.4.1. Standard stock solutions (1 mg/mL) and (100 µg/ml)	108
IV.2.4.2. Standard working solutions	109
IV.2.4.3. Calibration and quality control samples	109
IV.2.5. Procedure	109
IV.2.6. Method validation	110
IV.2.6.1. Selectivity	110
IV.2.6.2. Linearity and range	110
IV.2.6.3. Accuracy and precision.....	111
IV.2.6.4. Recovery, matrix effect, and carryover	111
IV.2.6.5. Stability.....	112
IV.2.6.5.1. Freeze and thaw stability	112
IV.2.6.5.2. Benchtop stability	112
IV.2.6.5.3. Long-term stability	112
IV.2.6.5.4. Processed sample stability	112
IV.2.6.5.5. Stock solution stability	112
IV.2.7. Applications.....	113
IV.2.7.1. Application to rat serum and brain tissue samples	113
IV.2.7.1.1. Extraction procedure for rat serum samples	113
IV.2.7.1.2. Extraction procedure for rat brain tissue samples	114
IV.2.7.1.3. Pharmacokinetic parameters.....	114
IV.3. Results and discussion	114
IV.3.1. LC-MS/MS method development	115
IV.3.1.1 Optimization of mass spectrometric parameters conditions	115
IV.3.1.2. Optimization of Chromatographic conditions	115
IV.3.2. Optimization of sample extraction procedure	116

IV.3.3. Selection of the internal standard	117
IV.3.4. Method validation	117
IV.3.4.1. Selectivity	117
IV.3.4.2. Linearity and range	117
IV.3.4.3. Accuracy and precision.....	118
IV.3.4.4. Recovery, matrix effect, and carryover	119
IV.3.4.5. Stability	119
IV.3.5. Quantification of oxycodone and cocaine in rat serum and brain samples	120
IV.3.5.1. Pharmacokinetics parameters	120
IV.4. Conclusion	121

Part V: Spectrophotometric determination of some drugs of abuse

Section A: Simultaneous determination of Tramadol and Paracetamol by First derivative ratio spectrophotometric method

V.A.1. Introduction	146
V.A.2. Experimental	146
V.A.2.1. Apparatus	146
V.A.2.2. Materials.....	147
V.A.2.2.1. Pure standards	147
V.A.2.2.2. Pharmaceutical formulation	147
V.A.2.2.3. Chemical	147
V.A.2.2.4. Standard solution.....	147
V.A.2.2.4.1. PAR stock standard solution (100 µg/mL)	147
V.A.2.2.4.2. TRA stock standard solution (1 mg/mL)	147
V.A.2.3. Procedure.....	148

V.A.2.3.1. Spectral characteristics of TRA and PAR	148
V.A.2.3.2. Method Validation	148
V.A.2.3.2.1. Linearity	148
V.A.2.3.2.2. Accuracy	149
V.A.2.3.2.3. Precision	149
V.A.2.3.2.3.1. Repeatability (Intraday precision).....	149
V.A.2.3.2.3.2. Intermediate precision (Interday precision)	149
V.A.2.3.2.4. Specificity	149
V.A.2.3.2.5. Limit of Detection (LOD), and Limit of Quantitation (LOQ)	150
V.A.2.3.3. Application of the proposed method for the determination of PAR and TRA in pharmaceutical formulation (Zaldiar®)	150
V.A.3. Results and discussion.....	151
V.A.4. Conclusion	153

Section B: Simultaneous determination of Tramadol and Paracetamol by mean centering spectrophotometric method

V.B.1. Introduction	164
V.B.2. Experimental	164
V.B.2.1. Apparatus.....	164
V.B.2.2. Software.....	164
V.B.2.3. Materials	164
V.B.2.3.1. Pure standards.....	164
V.B.2.3.2. Pharmaceutical formulation	165
V.B.2.3.3. Chemical.....	165
V.B.2.3.4. Standard solutions	165

V.B.2.4. Procedure.....	165
V.B.2.4.1. Spectral characteristics of TRA and PAR	165
V.B.2.4.2. Method Validation	165
V.B.2.4.2.1. Linearity	165
V.B.2.4.2.2. Accuracy.....	166
V.B.2.4.2.3. Precision	166
V.B.2.4.2.3.1. Repeatability (Intraday precision).....	166
V.B.2.4.2.3.2. Intermediate precision (Interday precision)	166
V.B.2.4.2.4. Specificity.....	166
V.B.2.4.2.5. Limit of Detection (LOD), and Limit of Quantitation (LOQ)	167
V.B.2.4.3. Application of the proposed method for the determination of PAR and TRA in pharmaceutical formulation (Zaldiar®)	167
V.B.3. Results and discussion.....	167
V.B.4. Conclusion	170

Section C: Simultaneous determination of Tramadol and Paracetamol by dual wavelength spectrophotometric method

V.C.1. Introduction	179
V.C.2. Experimental	179
V.C.2.1. Apparatus.....	179
V.C.2.2. Materials	179
V.C.2.2.1. Pure standards.....	179
V.C.2.2.2. Pharmaceutical formulation	179
V.C.2.2.3. Chemical.....	180
V.C.2.2.4. Standard solution.....	180

V.C.2.3. Procedure.....	180
V.C.2.3.1. Spectral characteristics of TRA and PAR	180
V.C.2.3.2. Method Validation	180
V.C.2.3.2.1. Linearity	180
V.C.2.3.2.2. Accuracy.....	180
V.C.2.3.2.3. Precision	181
V.C.2.3.2.3.1. Repeatability (Intraday precision).....	181
V.C.2.3.2.3.2. Intermediate precision (Interday precision)	181
V.C.2.3.2.4. Specificity.....	181
V.C.2.3.2.5. Limit of Detection (LOD), and Limit of Quantitation (LOQ)	181
V.C.2.3.3. Application of the proposed method for the determination of PAR and TRA in pharmaceutical formulation (Zaldiar®)	182
V.C.3. Results and discussion.....	182
V.C.4. Conclusion	184

Section D: General Discussion

V.F. General discussion	194
References	197

List of figures

Figure 1: Representative HPLC chromatogram of the pure 3 compounds at 215 nm and 235 nm using the specified chromatographic conditions. 10 µg/mL from each of Cocaine, Methadone, and L-THP (internal standard) at 2.8, 5.3, and 6.5 min respectively.	86
Figure 2: Linearity of the peak area ratio versus the corresponding concentration of Methadone (0.05-10 µg/mL) in serum, and brain using the proposed HPLC-UV meth.	87
Figure 3: Linearity of the peak area ratio versus the corresponding concentration of Cocaine (0.05-10 µg/mL) in serum, and brain using the proposed HPLC-UV method.	88
Figure 4: Representative HPLC chromatogram of blank rat serum using the specified chromatographic conditions.	89
Figure 5: Representative HPLC chromatogram of blank rat brain homogenate using the specified chromatographic conditions.	89
Figure 6: Representative HPLC chromatograms of rat serum spiked with methadone, cocaine and L-THP (internal standard) at the LLOQ (0.05 µg/mL) using the specified chromatographic conditions. Retention times of cocaine, methadone, and L-THP are 2.9, 5.6, and 6.4 min; respectively.	90
Figure 7: Representative HPLC chromatograms of rat brain homogenate spiked with methadone, cocaine and L-THP (internal standard) at the LLOQ (0.05 µg/mL), using the specified chromatographic conditions. Retention times of cocaine, methadone, and L-THP are 3, 5.7, and 6.4 min; respectively.	91
Figure 8: Representative HPLC chromatograms of rat serum spiked with methadone, cocaine and L-THP (internal standard) at the ULOQ (10 µg/mL), using the specified chromatographic conditions. Retention times of cocaine, methadone, and L-THP are 2.9, 5.1, and 6.5 min; respectively.	92
Figure 9: Representative HPLC chromatograms of rat brain homogenate spiked with methadone, cocaine and L-THP (internal standard) at the ULOQ (10 µg/mL), using the specified chromatographic conditions. Retention times of cocaine, methadone, and L-THP are 2.9, 5.4, and 6.4 min; respectively	93
Figure 10: Representative HPLC chromatograms of rat serum samples at C _{max} post i.p administration of methadone and cocaine at 7 mg/kg and 10 mg/kg; respectively.	94
Figure 11: Representative HPLC chromatograms of rat serum samples at C _{min} post i.p administration of methadone and cocaine at 7 mg/kg and 10 mg/kg; respectively.	95

Figure 12: Representative HPLC chromatograms of rat brain homogenate samples at $C_{\max}$ post i.p administration of methadone and cocaine at 7 mg/kg and 10 mg/kg; respectively.....	96
Figure 13: Representative HPLC chromatograms of rat brain homogenate samples at $C_{\min}$ post i.p administration of methadone and cocaine at 7 mg/kg and 10 mg/kg; respectively.....	97
Figure 14: Cocaine serum and brain concentrations vs time profiles after i.p. administration of cocaine (10 mg/kg) alone vs in the presence of methadone (7 mg/kg) to male Sprague Dawley rats.....	98
Figure 15: Methadone serum and brain concentrations vs time profiles after i.p. administration of methadone (7 mg/kg) in the presence of cocaine (10 mg/kg) to male Sprague Dawley rats.	99
Figure 16: Mass spectrum for the pure oxycodone and oxycodone-d ₃ and their fragmentation products.....	122
Figure 17: Linearity of the peak area ratio versus the corresponding concentration of oxycodone (0.01-2 µg/mL) in serum, and brain using the proposed UPLC-MS/MS method.....	123
Figure 18: Representative UPLC-MS/MS chromatogram of blank rat serum using the specified chromatographic conditions.....	124
Figure 19: Representative UPLC-MS/MS chromatogram of blank rat brain homogenate using the specified chromatographic conditions.....	125
Figure 20: Representative UPLC-MS/MS chromatograms of rat serum spiked with oxycodone and oxycodone-D ₃ (internal standard) at the LLOQ (0.01 µg/mL) using the specified chromatographic conditions. Retention times of both oxycodone and oxycodone-D ₃ is 2.2 min.....	126
Figure 21: Representative UPLC-MS/MS chromatograms of rat brain homogenate spiked with oxycodone and oxycodone-D ₃ (internal standard) at the LLOQ (0.01 µg/mL) using the specified chromatographic conditions. Retention times of both oxycodone, and oxycodone-D ₃ is 2.2 min.	127
Figure 22: Representative UPLC-MS/MS chromatograms of rat serum spiked with oxycodone and oxycodone-D ₃ (internal standard) at the ULOQ (2 µg/mL) using the specified chromatographic conditions. Retention times of both oxycodone, and oxycodone-D ₃ is 2.2 min.	128
Figure 23: Representative UPLC-MS/MS chromatograms of rat brain homogenate spiked with oxycodone and oxycodone-D ₃ (internal standard) at the ULOQ (2 µg/mL) using the specified chromatographic conditions. Retention times of both oxycodone and oxycodone-D ₃ is 2.2 min.	129
Figure 24: Representative UPLC-MS/MS chromatograms of rat serum samples at $C_{\max}$ post i.p administration of oxycodone, and cocaine at 5 mg/kg, and 10 mg/kg; respectively.	130
Figure 25: Representative UPLC-MS/MS chromatograms of rat serum samples at $C_{\min}$ post i.p administration of oxycodone, and cocaine at 5 mg/kg, and 10 mg/kg respectively.	131